Adjuvant Pembrolizumab Notably Improves OS vs Placebo in ccRCC
Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.
Early Efficacy of ASKB589 with CAPOX and Sintilimab in Gastric/GEJ Cancers: Promising Results Unveiled
ASKB589 exhibited anti-tumor activity when used alongside capecitabine and oxaliplatin, along with sintilimab, for the treatment of gastric or gastroesophageal junction cancers.
Trastuzumab Deruxtecan/Endocrine Therapy Shows Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki showed promising antitumor activity in patients with chemotherapy-naïve, HER2-low, hormone receptor-positive metastatic breast cancer.
IO Doublets Lead to Survival Benefit Over Chemotherapy in PD-L1-Negative NSCLC
Survival benefits for immunotherapy doublets outweigh chemotherapy alone in advanced stage PD-L1-negative non-small cell lung cancer.
Evaluating Belzutifan Its Approval for Cancers Associated With VHL Disease
In a presentation at the 2023 International Kidney Cancer Symposium, Jaleh Fallah, MD, discussed the regulatory agency’s evaluation of data from the phase 2 LITESPARK-004 trial, which led to the approval of belzutifan.
Dato-DXd Shows Significant PFS Benefit vs Docetaxel in Advanced NSCLC
Treatment with datopotamab deruxtecan improved progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer.
Evidence of Activity with Etigilimab Plus Nivolumab Seen in Recurrent/Advanced Solid Tumors
The emergence of preliminary efficacy evidence, and potential biomarker targets, with the combination of the novel anti-TGIT agent etigilimab and nivolumab was presented at the 2023 ESMO Congress.
Pembrolizumab/Chemoradiotherapy Shows Clinically Meaningful PFS Improvement in Cervical Cancer
Data from the KEYNOTE-A18 trial support the addition of pembrolizumab to chemoradiotherapy, which has been in place as standard of care for patients with newly diagnosed, previously untreated, high-risk locally advanced cervical breast cancer since 1999.
Venetoclax-Based Triplet Demonstrates Early Efficacy in t(11;14)-Positive RRMM
Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.
Adagrasib Induces Durable Efficacy in KRAS G12C-Mutant NSCLC
According to Shirish M. Gadgeel, MD, adagrasib demonstrated durable clinical benefit [and] there were no new safety signals.
Continued Benefit With Nivolumab Plus Relatlimab Shown in Advanced Melanoma
Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.
Lasofoxifene/Abemaciclib Shows Significant Anti-Tumor Efficacy in ER+/HER2- ESR1-Mutant Breast Cancer
Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.
Elacestrant Shows Survival Benefit in Certain ER+/HER2- Advanced Breast Cancer
A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.
Clinically Meaningful Efficacy Shown With Cabozantinib Plus Nivolumab/Ipilimumab in RCCvh
The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.
Envafolimab, Lenvatinib, and TACE Elicits Promising Efficacy/Safety in Unresectable HCC
Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Cilta-Cel Shows Potential to Fill A Treatment Gap in Early-Line Multiple Myeloma
Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.
Zanubrutinib Benefits Acalabrutinib-Intolerant Patients With B-Cell Malignancies
Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.
Trastuzumab Deruxtecan +/– Pertuzumab Shows Early Safety/Efficacy in HER2+ mBC
In the phase 1b/2 DESTINY-Breast07 study, positive results were shown with trastuzumab deruxtecan, even without the addition of pertuzumab.
2 Commerce Drive Cranbury, NJ 08512